Research demonstrates TBC1D15 modulation reverses resistance to TMZ in glioblastoma, suggesting lysosomal dysfunction may influence treatment outcomes.
Key Points
TBC1D15 knockdown significantly sensitize glioblastoma cells to TMZ, reversing drug resistance.
Lysosomal Ca²⁺ dynamics are altered by TBC1D15 modulation, impacting TFEB nuclear translocation and Cx43 expression.
Dutasteride, identified as a TBC1D15 inhibitor, enhances TMZ sensitivity in glioblastoma cell lines and in vivo models.
This research highlights a potential therapeutic strategy for overcoming treatment resistance in glioblastoma patients.